Bruce Horowitz - Jun 17, 2021 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
COO, Director
Signature
/s/ Bruce Horowitz
Stock symbol
PVCT
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
4
Date filed
6/22/2021, 05:23 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Secured Convertible Promissory Notes due 2021 Award $110K $110K Jun 17, 2021 Series D-1 Convertible Preferred Stok 38.5K $2.86 Direct F1
transaction PVCT 8% Secured Convertible Promissory Notes due 2021 Options Exercise -$110K 0 Jun 20, 2021 Series D-1 Convertible Preferred Stock 38.5K $2.86 Direct F2
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +38.5K $0.00 38.5K Jun 20, 2021 Common Stock 385K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer issued the 8% secured convertible promissory notes due 2021 to the Reporting Person on March 18, 2020 (the "Notes"). At the time of issuance, the Issuer had not filed a Certificate of Designation for the Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Convertible Preferred Stock") and, therefore, there was no security underlying the Notes into which the Notes could convert. On June 17, 2021, the Issuer filed a Certificate of Designation with the Delaware Secretary of State to create the Series D-1 Convertible Preferred Stock and, upon the filing of the Certificate of Designation, the Notes became a derivative security.
F2 On June 20, 2021, the Notes automatically converted into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share in accordance with the terms of the Notes.
F3 Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F4 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.